Understand the source comparison
Comparison: Mazdutide Week by Week vs Semaglutide and Tirzepatide
| Medication | Mechanism | Weeks 1-12 Loss | Weeks 13-24 Loss | Weeks 25-48 Loss | Final % Reduction (48 weeks) | Bottom Line ||—|—|—|—|—|—|| Mazdutide 6mg | Dual GLP-1/glucagon agonist | 6.8% | 5.8% | 5.6% | 18.2% | Slower start, sustained long-term trajector
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Medication | Mechanism | Weeks 1-12 Loss | Weeks 13-24 Loss | Weeks 25-48 Loss | Final % Reduction (48 weeks) | Bottom Line ||—|—|—|—|—|—|| Mazdutide 6mg | Dual GLP-1/glucagon agonist | 6.8% | 5.8% | 5.6% | 18.2% | Slower start, sustained long-term trajectory without plateau || Semaglutide 2.4mg | GLP-1 agonist | 9.2% | 4.1% | 1.6% | 14.9% (68 weeks) | Fastest early loss, plateaus after week 28 || Tirzepatide 15mg | Dual GLP-1/GIP agonist | 11.4% | 6.8% | 2.7% | 20.9% (72 weeks) | Highest total reduction, moderate plateau |
- Mazdutide's glucagon component produces the flattest weight loss curve. No sharp early drop followed by plateau, but rather consistent 0.3-0.5% weekly reduction across 48 weeks. For patients prioritizing fat mass specificity and metabolic health markers (liver fat, insulin sensitivity) over rapid scale changes, this profile may be preferable to GLP-1-only agonists.